{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:15:34Z","timestamp":1755216934478,"version":"3.43.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.japh.2025.102395","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T18:19:38Z","timestamp":1743358778000},"page":"102395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statin therapy prescribing in atherosclerotic cardiovascular disease patients with chronic kidney disease"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4604-1786","authenticated-orcid":false,"given":"Armen K.","family":"Fstkchian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-8148","authenticated-orcid":false,"given":"Rachel N.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-5140","authenticated-orcid":false,"given":"Joseph J.","family":"Saseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.japh.2025.102395_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.japh.2025.102395_bib2","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.japh.2025.102395_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.japh.2025.102395_bib4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.japh.2025.102395_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.japh.2025.102395_bib6","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PC NA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.japh.2025.102395_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.japh.2025.102395_bib8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"9731","key":"10.1016\/j.japh.2025.102395_bib9","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.japh.2025.102395_bib10","article-title":"HMG CoA Reductase Inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"5","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.japh.2025.102395_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.japh.2025.102395_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006886","article-title":"High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"5","author":"Yan","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.japh.2025.102395_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010640","article-title":"Trends in statin use among US adults with chronic kidney disease, 1999\u20132014","volume":"8","author":"Mefford","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.japh.2025.102395_bib14","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ckj\/sfy131","article-title":"Low statin use in nondialysis-dependent chronic kidney disease in the absence of clinical atherosclerotic cardiovascular disease or diabetes","volume":"12","author":"Markossian","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.japh.2025.102395_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2369-14-132","article-title":"Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001\u20132010","volume":"14","author":"Kuznik","year":"2013","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.japh.2025.102395_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12944-023-01833-z","article-title":"International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?","volume":"22","author":"Calice-Silva","year":"2023","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.japh.2025.102395_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000784","article-title":"The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome","volume":"3","author":"Sarma","year":"2014","journal-title":"J Am Heart Assoc"},{"author":"Crestor [Package Insert]","key":"10.1016\/j.japh.2025.102395_bib19"},{"issue":"12","key":"10.1016\/j.japh.2025.102395_bib20","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/ndt\/gfh474","article-title":"Renal tubular toxicity of HMG-CoA Reductase Inhibitors","volume":"19","author":"van Zyl-Smit","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.japh.2025.102395_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2016.08.037","article-title":"Renal tubular toxicity associated with rosuvastatin therapy","volume":"69","author":"Ward","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.japh.2025.102395_bib22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0272-6386(96)90512-0","article-title":"The role of proteinuria in the progression of chronic renal failure","volume":"27","author":"Burton","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.japh.2025.102395_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00129784-200404020-00005","article-title":"Rosuvastatin: a review of its use in the management of dyslipidemia","volume":"4","author":"Scott","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"10.1016\/j.japh.2025.102395_bib24","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.japh.2025.102395_bib25","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"18","key":"10.1016\/j.japh.2025.102395_bib26","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jacc.2022.02.049","article-title":"Trends in high-intensity statin therapy after myocardial infarction among U.S. adults, 2011\u20132019","volume":"79","author":"Colantonio","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.japh.2025.102395_bib27","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.japh.2025.102395_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2016.09.007","article-title":"Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: practice impact of the new cholesterol guidelines","volume":"182","author":"Rodriguez","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.japh.2025.102395_bib29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ahj.2016.07.024","article-title":"Impact of the 2013 American College of Cardiology\/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke","volume":"181","author":"Valentino","year":"2016","journal-title":"Am Heart J"},{"issue":"4S","key":"10.1016\/j.japh.2025.102395_bib30","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"8A","key":"10.1016\/j.japh.2025.102395_bib31","doi-asserted-by":"crossref","first-page":"44C","DOI":"10.1016\/j.amjcard.2005.12.009","article-title":"Statin safety: lessons from new drug applications for marketed statins","volume":"97","author":"Jacobson","year":"2006","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.japh.2025.102395_bib32","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1681\/ASN.2022020135","article-title":"Association of rosuvastatin use with risk of hematuria and proteinuria","volume":"33","author":"Shin","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.japh.2025.102395_bib33","first-page":"628","article-title":"Abstract P628: The right dose for the right patient - high intensity rosuvastatin dosing in patients with chronic kidney disease","volume":"147","author":"Zitelny","year":"2023","journal-title":"Circulation"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T23:13:00Z","timestamp":1754349180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319125000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1544319125000743"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2025.102395","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin therapy prescribing in atherosclerotic cardiovascular disease patients with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2025.102395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102395"}}